BlackRock Amends MAXCYTE Stake Filing as of Dec 31, 2023
Ticker: MXCT · Form: SC 13G/A · Filed: Jan 26, 2024 · CIK: 1287098
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, passive-investment
TL;DR
**BlackRock still owns MAXCYTE stock, signaling continued institutional confidence.**
AI Summary
BlackRock Inc. filed an amended SC 13G/A on January 26, 2024, indicating its ownership of MAXCYTE, INC. Common Stock as of December 31, 2023. This filing updates their previous disclosure, showing their continued significant, but passive, stake in MAXCYTE. This matters to investors because BlackRock is a major institutional investor, and their continued holding suggests confidence in MAXCYTE's long-term prospects, even if the exact percentage of ownership isn't detailed in this snippet.
Why It Matters
BlackRock's continued passive ownership in MAXCYTE, INC. signals institutional confidence, which can reassure current and potential investors about the company's stability and future outlook.
Risk Assessment
Risk Level: low — This filing is a routine update from a passive investor and does not indicate any immediate risks or significant changes in company control.
Analyst Insight
An investor should view this as a routine update confirming BlackRock's continued, passive interest in MAXCYTE, INC. It doesn't signal an immediate buy or sell, but rather reinforces the company's standing among institutional holders. Further research into MAXCYTE's financials and business developments would be prudent.
Key Players & Entities
- BlackRock Inc. (company) — the entity filing the SC 13G/A
- MAXCYTE, INC. (company) — the subject company whose stock is being reported
- December 31, 2023 (date) — the date of the event requiring the filing
- January 26, 2024 (date) — the date the SC 13G/A was filed
- 57777K106 (string) — the CUSIP number for MAXCYTE, INC. Common Stock
Forward-Looking Statements
- BlackRock will maintain a significant, passive stake in MAXCYTE, INC. throughout 2024. (BlackRock Inc.) — medium confidence, target: December 31, 2024
- MAXCYTE, INC. will continue to attract institutional investment due to its industry classification. (MAXCYTE, INC.) — medium confidence, target: December 31, 2024
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G filing, as stated in the 'FORM TYPE: SC 13G/A' and 'SCHEDULE 13G (Amendment No: 2)' sections.
Who is the filer of this SC 13G/A?
The filer of this SC 13G/A is BlackRock Inc., as indicated under the 'FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BlackRock Inc.' section.
What company's stock is the subject of this filing?
The subject company whose stock is being reported is MAXCYTE, INC., as stated under 'SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: MAXCYTE, INC.' and 'MAXCYTE, INC. (Name of Issuer)'.
What was the 'Date of Event Which Requires Filing of this Statement'?
The 'Date of Event Which Requires Filing of this Statement' was December 31, 2023, as explicitly stated in the filing.
Under which rule was this Schedule 13G filed?
This Schedule 13G was filed under Rule 13d-1(b), as indicated by the '[X] Rule 13d-1(b)' checkbox on the cover page.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 26, 2024 regarding MAXCYTE, INC. (MXCT).